Please ensure Javascript is enabled for purposes of website accessibility

Emergent BioSolutions Will Manufacture AstraZeneca's COVID-19 Vaccine Candidate

By Taylor Carmichael – Jun 11, 2020 at 2:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The agreement is valued at approximately $87 million.

Small-cap Emergent BioSolutions (EBS 1.66%) has landed another contract to manufacture a possible COVID-19 vaccine, this time with European pharmaceutical giant AstraZeneca. Of course, the contract, said to be worth as much as $87 million, hinges on whether AstraZeneca's vaccine gets approved by the Food and Drug Administration for human use.   

Emergent is a contract development and manufacturing organization that has relationships with many biotech and pharmaceutical companies (not to mention the federal government). Back in April, it  inked a similar deal with Johnson & Johnson worth up to $135 million. 

multiple bottles of COVID-19 vaccine

Image source: Getty Images

The coronavirus vaccine race is heating up

The COVID-19 pandemic is rewriting the rule book when it comes to how fast a drug can go from preclinical development to regulatory approval. Health officials are now suggesting that a COVID-19 vaccine may be ready for broad public use by 2021. That's an extraordinarily rapid pace considering that the record for bringing a totally new vaccine to market is four years, and the process usually takes considerably longer. Of course, the size of the opportunity is vast (i.e. most of the world), so vaccine companies are lining up manufacturing capacity now, even though most of their candidates haven't made it through phase 1 clinical trials yet.

This has introduced a level of speculation in drug manufacturing stocks that wasn't there before. Typically, biotechs wait until their drugs are near approval before signing any manufacturing contracts. But with COVID-19, all bets are off. Maybe Emergent will be producing a billion vials of COVID-19 vaccine next year, or maybe not. We simply can't know. 

One biotech, Novavax, recently spent $167 million to buy a company in order to get more manufacturing capacity for its COVID-19 vaccine candidate. Another one, Moderna, signed a 10-year COVID-19 vaccine manufacturing deal with the Swiss multinational Lonza Group.

Shares of Emergent were down by about 1.3% in mid-afternoon trading Thursday, while the broader market as measured by the S&P 500 was down by 4.8%. 

Taylor Carmichael owns shares of Novavax. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
$21.42 (1.66%) $0.35
Johnson & Johnson Stock Quote
Johnson & Johnson
$165.62 (1.48%) $2.42
Novavax, Inc. Stock Quote
Novavax, Inc.
$19.40 (4.30%) $0.80
Lonza Group Ltd Stock Quote
Lonza Group Ltd
$52.09 (5.08%) $2.52
Moderna, Inc. Stock Quote
Moderna, Inc.
$125.67 (3.87%) $4.68
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$113.00 (1.57%) $1.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.